At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
In Brief
A Phase 2 clinical trial evaluating Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), and 1 other intervention for HIV Infection and Hepatitis C Infection. Completed, enrolled 68 participants across 18 sites in 2 countries.
Detailed Summary
Infection with hepatitis C virus (HCV) can cause liver scarring, or cirrhosis, and this usually occurs more rapidly among people infected with both HCV and human immunodeficiency virus (HIV). People infected with both HCV and HIV have poor response to the current HCV treatments. This phase II pilot study evaluated whether adding a new HCV medication improves response to the current standard HCV treatment with pegylated interferon and ribavirin in people with both HCV and HIV.
Study Details
Timeline
Interventions
500 mg twice daily, taken orally with food
180 micrograms via subcutaneous injection once weekly
Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.